On May 15, 2014, Coe, Jotham Wadsworth; Allen, John Arthur; Davoren, Jennifer Elizabeth; Dounay, Amy Beth; Efremov, Ivan Viktorovich; Gray, David Lawrence Firman; Guilmette, Edward Raymond; Harris, Anthony Richard; Helal, Christopher John; Henderson, Jaclyn Louise; Mente, Scot Richard; Nason, Deane Milford, II; O’Neil, Steven Victor; Subramanyam, Chakrapani; Xu, Wenjian published a patent.Formula: C8H7BrN2 The title of the patent was Preparation of heteroaromatic compounds and their use as dopamine D1 ligands for therapy. And the patent contained the following:
The present invention provides, in part, compounds of Formula I (wherein X1 is O or S; Y1 is O, S, or (un)substituted NH; Q1 is Ph, or a N-containing 5-10-membered heterocycloalkyl or heteroaryl, all optionally substituted; RT1 and RT2 are independently H, C1-3-alkyl, cyclopropyl, etc.; R1 is H, F, -C(O)OH, C1-3-fluoroalkyl, etc.; R2 is H, halogen, -CN, -OH, C(O)OH, etc.; R3 and R4 are independently H, C1-6 alkyl, C1-6 haloalkyl, etc.; R5 and R6 are independently H, halogen, -OH, -NO2, -CN, etc.) and pharmaceutically acceptable salts thereof and N-oxides thereof; processes and intermediates for preparation of; and compositions and uses thereof. The present invention further provides D1 agonists with reduced D1R desensitization, D1 agonists with a reduced 尾-arrestin recruitment activity relative to dopamine, D1 agonists interacting significantly with Ser188 but not significantly with Ser202 of a D1R when binding to the D1R, D1 agonists interacting less strongly with both Asp103 and Ser198 of a D1R when binding to the D1R, and their uses in treating neurol., psychiatric and endocrine disorders. Example compound II was prepared in a multistep synthesis that culminated in reaction of intermediate III with 5-bromo-4,6-dimethylpyrimidine. In a human D1 receptor binding assay, II had a Ki of 27.3 nM. The experimental process involved the reaction of 5-Bromo-6-methylimidazo[1,2-a]pyridine(cas: 1346157-13-8).Formula: C8H7BrN2
The Article related to preparation heteroaromatic compound dopamine d1 ligand therapy, Heterocyclic Compounds (More Than One Hetero Atom): Fused-Ring Systems With Two Or More Hetero Atoms, No More Than One Hetero Atom Per Ring and other aspects.Formula: C8H7BrN2
Referemce:
Imidazole – Wikipedia,
Imidazole | C3H4N2 – PubChem